### Guidelines for the use of anti-TNFα therapy in Psoriatic Arthritis

#### 1. Active Psoriatic Arthritis

 $\geq$ 3 tender and  $\geq$ 3 swollen joints on 2 separate occasions 1 month apart.

#### 2. Failure of standard therapy

Adequate therapeutic trial of at least 2 standard DMARDs (Sulfasalazine, Methotrexate, Ciclosporin or Leflunomide). An adequate therapeutic trial is defined as:

- Treatment for at least 6 months, with at least 2 months at standard target dose (SZP 2g/day, MTX 20mg/week, CYS 3-5mg/kg/day, LEF 20mg/day) unless significant toxicity limits the dose.
- Treatment for < 2 months, where treatment is withdrawn because of drug intolerance or toxicity. When treatment is withdrawn after > 2 months, at least 2 months should have been at therapeutic doses (SZP 1-2g/day, MTX 7.5mg/week, CYS 3mg/kg/day, LEF 10mg/day).

#### 3. Exclusion criteria

- Women who are pregnant or breast feeding. Effective contraception is strongly recommended to prevent pregnancy in women of child-bearing potential.
- Active infection (See BSR/BTS guidelines for TB)
- Septic arthritis of a native joint within the last 12 months
- Sepsis of a prosthetic joint within the last 12 months or indefinitely if the joint remains in situ.
- New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure (CCF).
- Clear history of demyelinating disease.
- Extreme caution in patients prone to infections (chronic leg ulcers, persistent or recurrent chest infections, indwelling urinary catheters). For Hepatitis B, C and HIV check BSR guidelines.
- Caution if :
  - o Underlying pulmonary fibrosis,
  - Premalignant conditions.
  - Previous malignancy (except when patients have been free of any recurrence of their malignancy for 10 years).
  - PUVA therapy >1000 Joules especially if ciclosporin was prescribed after PUVA (as there is an increase risk of skin malignancy). Inform the Dermatologist, as the patient will require annual skin checks.
  - Past history of TB or close contact with TB (See BSR/BTS guidelines)

#### 4. Response to therapy

#### A/ Joint response (PsARC)

Improvement of two factors (with at least one being a joint sore) with worsening of none of the following 4 factors. Dactylitis, but not enthesitis, should be counted as one active joint:

- Patient global assessment (0-5 Likert scale)
- Physician global assessment. (0-5 Likert Scale)

(Improvement defined as decrease by  $\geq 1$  unit; worsening defined as increase by  $\geq 1$  unit.)

- Tender joint score
- Swollen joint score

(Improvement defined as decrease by  $\geq$ 30%, worsening defined as increase  $\geq$ 30%)

#### **B/ Skin response**

PASI 75 for primary response of psoriasis.

All patients with "significant" skin psoriasis should be referred to Dermatology for the PASI score to be done.

Patients being reviewed in the Photobiology unit should be referred to either Professor Ferguson or Dr Ibbotson. For all other patients a referral should be made to Dr Lewis-Jones.

Those patients attending PRI rheumatology clinics should be referred to Dr Heather Cameron.

#### C/ Other data collection recommended

- ESR/ PV
- CRP
- HAQ

#### 5. Choice of Drug

There are currently two anti-TNF drugs accepted by the SMC for psoriatic arthritis: etanercept and adalimumab. There is little to chose between them in terms of efficacy or toxicity. They differ in dose and frequency of administration (see below). If a patient fails on one then it is usually reasonable to try the other. If a patient has toxicity on one then the other may be considered.

#### 6. Withdrawal of therapy

- If no joint response by 3-6 months (if significant skin response discuss with dermatologist)
- Malignancy
- Severe drug related toxicity
- Pregnancy (temporary withdrawal)
- Intercurrent infection (temporary withdrawal)
- Surgical procedures (temporary withdrawal from 2-4 weeks preoperatively until 2 weeks postoperatively if no infection and wound healing satisfactory).

# Please note that all severe side effects should be reported to MHRA (Medicines and Healthcare products Regulatory Agency) by completing a yellow card.

- 7. TB Screening As per BSR/ BTS guidelines
- Dose: Etanercept 25mg by subcutaneous injection administered twice a week or 50mg administered once weekly. Adalimumab 40mg by subcutaneous injection every 2 weeks.
- 9. If a patient fulfils the criteria for anti-TNF treatment:
  - Check permission has been granted by Medical Director (Dr Winter)
  - Letter to Medical Director (Dr Winter) and Senior Pharmacist (Gordon Thomson)
  - Complete the "Healthcare at Home" registration form and prescription and send it to Gordon Thomson
  - **Baseline investigations**: FBC, U&Es, LFTs, PV, CRP, ANA CXR and Heaf test as per TB screening guidelines.
  - **Blood monitoring**: As recommended for any DMARD being used concomitantly. If not on any DMARDs, bloods every clinic visit though depending upon the pattern of the blood count more frequent monitoring may be advised by the rheumatology clinic.
  - Clinic appointments:
    - 6 weeks after starting treatment (safety check)
    - o 3 months after starting treatment (Assessment)
    - o 6 months after starting treatment (Assessment)
    - o 6 monthly appointments unless clinically indicated
    - If the patient develops an infection or WBC< 4.0x10<sup>9</sup>/l, Neutrophils
      < 2.0 x10<sup>9</sup>/l or platelets <150 x10<sup>9</sup>/l the on call rheumatologist (via switchboard) or Biologics Nurse specialist (ext 32336 N/W or

13529 - PRI) should be contacted.

## Psoriatic Arthritis Baseline Questionnaire

Title:		Surname:
Forename:		
Address:		
Postcode:		
Telephone number:		
Gender:	Male	Female
Date of birth:		
Hospital number:		
NHS number:		
Consultant Rheumato	logist:	
GP Name:		
Today's date:		
Biologic to be comme	enced:	

1. Does the patient have Psoriatic Arthritis?

Yes/ No

2. Psoriatic Arthritis criteria:

Skin Psoriasis:

Yes

No

3. Drug therapy: Please list all the patient's current treatment

#### 4. Previous Biologic therapy

Name of therapy:

Date of first biologic therapy dose:

Average dose:

Is this the patient's first exposure to a biologic agent? Yes No

#### 5. Previous second-line drug therapy

Methotrexate:	Yes	No			
Sulphasalazine:	Yes	No			
Cyclosporine:	Yes	No			
Leflunomide:	Yes	No			
Other, please specify:					
Does the patient	Yes				
Has the patient e	Yes				

No

No

#### 6. Co-morbidity:

Heart failure

Pulmonary fibrosis

Bronchiectasis

#### ΤВ

#### Demyelination

Hypertension

Angina

MI

Stroke

Epilepsy

Asthma

Chronic bronchitis

Peptic ulcer

Liver disease

Renal disease

Diabetes - If yes, specify type	
Hyperthyroidism	
Depression	
Cancer - If yes, specify site and year	
Other rheumatic condition	-

11. Did the patient have a Chest X- ray prior to starting new therapy?

Yes No

12. Did the patient have a Heaf test prior to starting new therapy?

Yes	No
-----	----

#### 13. Clinical assessment: Is there evidence of?

TB or previous TB:	Yes	No
Previous TB contact	Yes	No
Congestive heart failure:	Yes	No
Infections:	Yes	No
Demyelination:	Yes	No

Data Collection	Baseline	3 Months	6 Months	6 Monthly for 3 years then yearly
PsARC response				
Tender joint count	-			
Swollen joint count				
Patient global health (0-5)				
Physicians global health (0- 5)				
FBC				
U&E's/ LFT's				
ESR/ CRP				
ANA		X	X	X
HAQ				
<b>PASI score</b> (if significant skin psoriasis)				
Record				
illness/surgery				
Skin checks				<b>Annually</b> ( if previous high doses of PUVA/UVB)
<b>TB Screening</b> (as per BTS guidelines)		X	X	X

#### A/ Joint scores

Joints included in the 78 and 76 swollen joint count.

- Joints should be assessed for presence or absence of swelling and tenderness (0-1)
- Replaced and damaged joints should not be included in assessment

JOINT	ia aamagea jen	RIGHT		LEFT
	Tender	Swollen	Tender	Swollen
Temp Mandib.				
Sterno. clav				
Acro. Clav.				
Shoulder				
Elbow				
Wrist				
CMC				
MCP1				
MCP2				
MCP3				
MCP4				
MCP5				
PIP1				
PIP2				
PIP3				
PIP4				
PIP5				
DIP2				
DIP3				
DIP4				
DIP5				
Hip		XXXXXX		XXXXXX
Knee				
Ankle				
Tarsi				
MTP1				
MTP2				
MTP3				
MTP4				
MTP5				
Toes (PIP)1				
PIP2				
PIP3				
PIP4				
PIP5				
Toes (DIP)2				
DIP3				
DIP4				
DIP5				

#### B/ Psoriasis Area and Severity Index (PASI)

Tick one box for each region A, B, C, D

		Head (h)	Upper limb (u)	Lower limb (I)	Trunk (t)
A. Extent of	None (0)				
involvement (%)	<10 (1)				
Tick one box	10-30 (2)				
for each body region	30-50 (3)				
	50-70 (4)				
	70-90 (5)				
	90-100 (6)				
B. Erythema (E)	None (0)				
score	Slight (1)				
	Moderate(2)				
	Severe (3)				
	Very severe(4)				
C. Infiltration (I)	None (0)				
score	Slight (1)				
	Moderate(2)				
	Severe (3)				
	Very severe(4)				
D. Desquamation	None (0)				
(D) score	Slight (1)				
	Moderate(2)				
	Severe (3)				
	Very severe(4)				

**Score** = 0.1 (Eh +Ih + Dh) Extent (h) + 0.2 (Eu + Iu + Du) Extent (u) + 0.4(El + II + Dl) Extent (l) + 0.3 (Et + It + Dt) Extent (t)

Total PASI score \_\_\_\_\_

#### C/ Health Assessment Questionnaire

Name.....

Date.....

We are interested in learning how your illness affects your ability to function in daily life. Please feel free to add any comments at the end of this form.

## PLEASE TICK ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES OVER THE PAST WEEK

	Without ANY difficulty	With SOME difficulty	With MUCH difficulty	Unable to do
1. DRESSING AND GROOMING -				
Are you able to:				
Dress yourself, including tying				
Shoelaces and doing buttons?				
Shampoo your hair?				
2. RISING -				
Are you able to:				
Stand up from an armless straight				
chair?				
Get in and out of bed?				
3. EATING -				
Are you able to:-				
Cut your meat?				
Lift a full glass to your mouth?				
Open a new carton of milk (or soap				
Powder)?				
4. WALKING -				
Are you able to:				
Walk outdoors on flat ground?				
Climb up 5 steps?				

#### Please tick any devices that you usually use for any of these activities:-

Cane Crutches Device used for dressing (bu	Wheelchair		
Built up or special utensils chair		Special or built up	
Please tick any categories f Dressing and grooming	•	ally need help from another person Eating	:-

••

	Without ANY difficulty	With SOME Difficulty	With MUCH Difficulty	Unable to do
5. HYGIENE -				
Are you able to:				
Wash and dry your entire body?				
Take a bath?				
Get on and off the toilet?				
6. REACH -				
Are you able to:				
Reach and get down a 5 lb object				
(e.g. a bag of potatoes) from just				
above your head?				
Bend down to pick up clothing				
from the floor?				
7. GRIP -				
Are you able to:-				
Open car doors?				
Open jars which have previously				
been opened?				
Turn taps on and off?				
8. ACTIVITIES -				
Are you able to:				
Run errands and shop?				
Get in and out of a car?				
Do chores such as vacuuming,				
housework or light gardening				

#### Please tick any aids or devices that you usually sue for any of these activities:

v	•	•		
Raised toilet seat	Bath rail.		Bath seat	
Long handled appliances for reach			Other (please	
specify)				
Jar opener (for jars previously opened	d)			

#### Please tick any category for which you usually n need help from another person:

Hygiene	Gripping and opening things
Reach	
Errands and housework	